Abstract 1487P
Background
Information and Communication Technology-based self-management support has been demonstrated to be effective in relieving symptoms for patients with advanced cancer. This study aimed to evaluate the effectiveness of a telemonitoring system for cancer pain relief in outpatients with advanced cancer in Japan.
Methods
The study was conducted between December 2019 and February 2023. This study included patients attending Tohoku University Hospital as outpatients, regularly taking opioids for cancer pain, with a mean pain NRS of ≥3 in 24 hours. Participants were randomized into intervention and control groups in a 1:1 ratio. The intervention group received telemonitoring care using the Cancer Pain Monitoring System (CAPAMOS). This comprises five components: symptom checks, medication checks, graphical records, pain booklet, and contact with a telenurse (chats, phones, and video phones). Alerts were sent to a telenurse when a patient’s symptoms worsened. The control group maintained a pain diary. An assessment of pain (NRS), quality of life (VAS), and opioid self-management scale (Opioid Self-Management Scale for Advanced Cancer Patients with Pain: OSSA) was conducted at baseline and after 2 and 4 weeks. Further, the Ethics Committee of Tohoku University Graduate School of Medicine reviewed the study (approval no. 2020-1-194).
Results
A total of 48 patients were enrolled in this study. There were no significant differences in baseline age (intervention 53.5 vs. control 57.0, p=0.68), severe pain (5.0 vs. 5.0, p=0.92), average pain (4.0 vs. 4.0, p=0.41), OSSA scores (135.0 vs. 130.0, p=0.06) and QOL (70.0 vs. 64.0, p=0.86) between groups. At 2 weeks post-intervention, no significant association was observed. At 1 month post-intervention, severe pain (5.0 vs. 5.5, p = 0.37), average pain (3.0, vs. 4.0, p = 0.41), OSSA scores (136.5 vs. 123.5, p=0.06), and QOL scores (57.5 vs. 50.0, p = 0.58) were not statistically significant. The scores for understanding pain characteristics in OSSA were significantly higher in the OSSA group than in the control group (10.0 vs. 8.0, p=0.04).
Conclusions
Telemonitoring support has led to educational advantages, such as improving patients’ understanding of opioid self-management and pain characteristics.
Clinical trial identification
UMIN000038334.
Editorial acknowledgement
Legal entity responsible for the study
Tohoku University Graduate School of Medicine.
Funding
JSPS KAKENHI.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1554P - Co payments in cancer patients: Analysis and estimating OOP
Presenter: Krishnamani Kalpathi
Session: Poster session 10
1555P - Estimating the social value of immuno-oncology (IO) therapies in Japan
Presenter: Tomoya Ohno
Session: Poster session 10
1556P - Current landscape of drug approvals for genitourinary (GU) cancers in North America and Europe
Presenter: Jose Tapia
Session: Poster session 10
1557P - The use of patient experience in UK NICE decision making in oncology
Presenter: Noemi Muszbek
Session: Poster session 10
1558P - Independent validation of the Breast Cancer Risk Assessment Tool (Gail model) for predicting breast cancer risk in Egyptian population
Presenter: Elaria Yacoub
Session: Poster session 10
1559P - Equity of access and clinical impact of genomic testing in patients with cancer in a UK early phase clinical trials unit
Presenter: Jonathan Poon
Session: Poster session 10
1560P - Optimal age versus real age in breast and gynaecological risk reducing surgery in BRCA1/2 carriers
Presenter: Alberta Ferrari
Session: Poster session 10
1561P - Targeted screening methodologies to select high risk individuals: LungFlag performance in Estonia Lung Cancer Screening Pilot
Presenter: Tanel Laisaar
Session: Poster session 10
1562P - The feasibility of polygenic risk score-based population screening for breast cancer: The experience from the BRIGHT study in Estonia
Presenter: Anni Lepland
Session: Poster session 10
1563P - Increasing the earlier detection of lung cancer: A toolbox for change
Presenter: Helena Wilcox
Session: Poster session 10